

events such as stroke and myocardial infarction, as well as cancer chemoprevention.

**Market:** (1) An estimated 60 million people in the United States use NSAIDs regularly; (2) An estimated \$5 billion are spent each year in the United States on prescription NSAIDs and approximately \$2 billion are spent on over-the-counter NSAIDs.

**Development Status:** Pre-clinical data is available.

**Inventors:** Carlos Velazquez Martinez (NCI) et al.

**Related Publication:** C Velazquez, PN Praveen Rao, EE Knaus. Novel nonsteroidal anti-inflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: Design, synthesis, biological evaluation, and nitric oxide release studies. *J Med Chem.* 2005 Jun 16;48(12):4061-4067.

**Patent Status:** U.S. Provisional Application 60/794,421 filed 24 Apr 2006 (HHS Reference No. E-186-2006/0-US-01).

**Licensing Status:** Available for exclusive and non-exclusive licensing.

**Licensing Contact:** Norbert Pontzer, Ph.D., J.D.; 301/435-5502; [pontzern@mail.nih.gov](mailto:pontzern@mail.nih.gov).

**Collaborative Research Opportunity:** The Chemistry Section of the Laboratory of Comparative Carcinogenesis is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the prodrugs described, as new and safer analgesic, anti-inflammatory, anti-thrombotic, and cancer chemopreventive agents. Please contact Betty Tong, Ph.D. at 301-594-4263 or [tongb@mail.nih.gov](mailto:tongb@mail.nih.gov) for more information.

### **Rat or Mouse Exhibiting Behaviors Associated With Human Schizophrenia**

**Description of Technology:** A newly developed animal model for schizophrenia is valuable for assaying pharmaceutical compounds for treating this disorder. Schizophrenia is a neuropsychiatric disorder characterized by cognitive deficits, bizarre behavior and/or hallucinations. Presently, there has been no satisfactory animal model for testing promising therapies for this disorder.

This invention provides a unique and surprisingly accurate animal model for human schizophrenia. The animals are brain damaged while prepubescent. The brain damage consists of a ventral hippocampus lesion induced by exposure of the hippocampus region to a neurotoxin. When the animal reaches puberty, abnormal behavior and a number of biological phenomena

associated with schizophrenic symptoms emerge.

The present invention also provides methods of assaying the anti-schizophrenic potential of pharmaceutical compositions. The methods involve (a) inducing or creating a lesion in the ventral hippocampus of a prepubescent mammal, (b) nurturing or raising the mammal until postpuberty, (c) administering to the mammal a pharmaceutical composition thought to have anti-schizophrenic properties; and (d) determining the mammal's response to the pharmaceutical composition. The anti-schizophrenic potential of the pharmaceutical composition is assessed by objectively measuring the mammal's behavior following administration of the pharmaceutical composition. The behaviors which are measured typically include the following: locomotor activity in a cage, in unfamiliar or novel environments, after injection or administration of drugs (e.g., amphetamines), after mild electric shock, after exposure to sensory stimuli (e.g., noise), in water (swim test), after immobilization, in social interactions, and in various learning and reward paradigms.

The neurotoxin used can be selected from a number of known agents which lethally affect neurons usually, but not exclusively, by over-exciting their glutamate receptors. Examples of such neurotoxins include ibotenic acid, N-methyl-D-aspartic acid, kainic acid, dihydrokainate, DL-homocysteate, L-cysteate, L-aspartate, L-glutamate, colchicine, ferric chloride, omega-conotoxin GVIA, 6-hydroxy-dopamine.

**Advantage:** This is the first model showing postpubertal emergence of abnormalities similar to those reported in schizophrenia.

**Applications:** (1) Animal model for human schizophrenia; (2) Screening methods for Anti-schizophrenics.

**Development Status:** Validated, well characterized and ready for use.

**Inventors:** Daniel R. Weinberger, Barbara K. Lipska, and George E. Jaskiw (NIMH).

#### **Publications:**

1. AHC Wong, BK Lipska, O Likhodi, E Boffa, DR Weinberger, JL Kennedy, HHM Van Tol. Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. *Schizophr Res.* 2005 Sep 15;77(2-3):261-270.

2. BK Lipska. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. *J Psychiatry Neurosci.* 2004 Jul;29(4):282-286.

3. BK Lipska and DR Weinberger. To model a psychiatric disorder in animals: schizophrenia as a reality test.

*Neuropsychopharmacology* 2000 Sep;23(3):223-239.

4. BK Lipska, GE Jaskiw, DR Weinberger. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic damage: a potential animal model of schizophrenia.

*Neuropsychopharmacology* 1993 Aug;9(1):67-75.

**Patent Status:** U.S. Patent No. 5,549,884 issued 27 Aug 1996 (HHS Reference No. E-013-1993/0-US-01).

**Availability:** Available for non-exclusive licensing.

**Licensing Contact:** Norbert Pontzer, Ph.D., J.D.; 301/435-5502; [pontzern@mail.nih.gov](mailto:pontzern@mail.nih.gov).

Dated: November 8, 2006.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E6-19408 Filed 11-15-06; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Human Genome Research Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Human Genome Research Institute Special Emphasis Panel; ENCODE RFA.

**Date:** December 6-7, 2006.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** The Watergate, 2650 Virginia Avenue, NW., Washington, DC 20037.

**Contact Person:** Rudy O. Pozzatti, PhD, Scientific Review Administrator, Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, 301 402-0838. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: November 7, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–9209 Filed 11–15–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel; Neural Tube Defects.

*Date:* November 28, 2006.

*Time:* 11 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Anne Krey, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, 301–435–6908.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel Children Living in Rural Poverty: The Continuation of the Family Life Project.

*Date:* November 30, 2006.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Jefferson, 2500 Calvert Street, NW., Washington, DC 20037.

*Contact Person:* Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892, (301) 435–6911, [hopmannm@mail.nih.gov](mailto:hopmannm@mail.nih.gov).

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel, A Prospective Study of Diet and Fibroids in Black Women.

*Date:* November 30, 2006.

*Time:* 10 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Jon M. Ranhand, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892, (301) 435–6884, [ranhandj@mail.nih.gov](mailto:ranhandj@mail.nih.gov).

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel Environmental & Biological Variation and Language Growth.

*Date:* December 5, 2006.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Jefferson Hotel, 1200 Sixteenth Street, NW., Washington, DC 20036.

*Contact Person:* Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892, (301) 435–6911, [hopmannm@mail.nih.gov](mailto:hopmannm@mail.nih.gov).

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel Translational Analyses of Chronic Aberrant Behavior Across the Life Span.

*Date:* December 6, 2006.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037.

*Contact Person:* Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892, (301) 435–6911, [hopmannm@mail.nih.gov](mailto:hopmannm@mail.nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: November 7, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–9210 Filed 11–15–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Drug Testing Advisory Board; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Substance Abuse and Mental Health

Services Administration (SAMHSA) Drug Testing Advisory Board in December 2006.

A portion of the meeting will be open and will include, but not limited to, a Department of Health and Human Services drug testing program update, a Department of Transportation drug testing program update, a Nuclear Regulatory Commission drug testing program update, an update on the pilot performance testing programs for hair and oral fluid, results from a Medical Review Officer data source, and results from a study on the external contamination of hair with cocaine.

Attendance by the public will be limited to space available. Public comments are welcome. Please communicate with Dr. Donna Bush, Executive Secretary (see contact information below), to make arrangements to comment or to request special accommodations for persons with disabilities.

The Board will also meet to develop the final revisions to the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs that were published in the **Federal Register** on April 13, 2004 (69 FR 19673). This meeting will be conducted in closed session since discussing these issues in open session will significantly frustrate the Department's ability to develop the revisions to the Mandatory Guidelines. The HHS Office of General Counsel made the determination that such matters are protected by exemption 9(B) of section 552b(c) of title 5 U.S.C. and, therefore, may be closed to the public.

To facilitate entering the building for the open session, public attendees are required to contact Mrs. Giselle Hersh, Division of Workplace Programs, 1 Choke Cherry Road, Room 2–1042, Rockville, MD 20857, 240–276–2605 (telephone) or by e-mail to [Giselle.Hersh@samhsa.hhs.gov](mailto:Giselle.Hersh@samhsa.hhs.gov).

Substantive program information and a roster of Board members may be obtained by contacting Dr. Bush or by accessing the SAMHSA workplace Web site (<http://workplace.samhsa.gov>). The transcript for the open session will be available on the SAMHSA workplace Web site within 3 weeks after the meeting.

*Committee Name:* Substance Abuse and Mental Health Services Administration Drug Testing Advisory Board.

*Meeting Date:* December 12–13, 2006.

*Place:* SAMHSA Building, Rock Creek Room 1, Choke Cherry Road, Rockville, Maryland 20850.

*Type:* Open: December 12, 2006; 8:30 a.m.–4:30 p.m.